CC-486 and Venetoclax for Acute Myeloid Leukemia

This study tests a combination of two drugs — CC-486 (an oral chemotherapy pill) and venetoclax — in people with a type of blood cancer called acute myeloid leukemia (AML). It includes both newly diagnosed patients who cannot tolerate standard intensive chemotherapy and patients whose AML has come back or stopped responding to treatment. **You may be eligible if...** - You have been diagnosed with AML (excluding a subtype called APL) - You have had at least one prior treatment (for relapsed/refractory patients), or you are newly diagnosed and cannot tolerate intensive chemotherapy - You are newly diagnosed and meet at least one of: age 75 or older; age under 75 with heart failure, poor heart function (EF ≤50%), significant lung disease, or reduced kidney function - You are willing to use contraception if applicable **You may NOT be eligible if...** - You have the APL subtype of AML - You are newly diagnosed and able to tolerate standard intensive chemotherapy - You have very poor kidney function (creatinine clearance under 30 mL/min) Talk to your doctor to see if this trial is right for you.